Oral drug bioavailability faces challenges due to poor solubility and permeability in many pharmaceutical compounds.
Our HyDES formulation technology specifically targets and enhances solubility and bioavailability for APIs, particularly those with high melting points and a weakly basic nature, thereby advancing oral drug delivery and therapeutic effectiveness.
The HyDES platform creates a hydrophilic eutectic solvent capable of incorporating up to 30% drug load, easily encapsulated in standard gelatin capsules. In humans, this formulation induces a supersaturated state, enhancing drug absorption. Demonstrated in a case study with Atazanavir, a notoriously insoluble drug, HyDES significantly raised bioavailability — over 700% compared to crystalline API and by more than 75% against an amorphous solid dispersion.
Atazanavir in vivo Case Study
Benefits of HyDES platform
Up to 25% drug loading
Significant bioavailability enhancement
What drug molecule is the eutectic platform suitable for?
Perfect formulation approach for API's that are:
(Weakly) basic High melting point